#United States #New York #Class Action #Rosen Law Firm #Altimmune

Call to Action for Altimmune Investors

Investors who purchased securities in Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023, and June 25, 2025, have a unique opportunity to take part in a class action lawsuit aimed at addressing potential securities fraud. The Rosen Law Firm, a esteemed global firm specializing in investor rights, has issued a reminder that the deadline to become the lead plaintiff is set for October 6, 2025.

What Does This Mean for You?

If you have experienced losses exceeding $50,000 from your investments in Altimmune during the designated class period, you may be eligible for compensation through a contingency fee arrangement. This means that you can participate without having to incur any upfront costs.

Steps to Take

Joining the class action is straightforward. Interested investors can fill out a form on Rosen Legal's website or contact Phillip Kim, Esq., either by phone at 866-767-3653 or via email at [email protected]. It’s essential to note that a class action lawsuit has already been initiated, and in order to serve as the lead plaintiff, you must file your motion with the court by the specified deadline.

Why Choose Rosen Law Firm?

Rosen Law Firm's reputation stems from its impressive track record in handling securities class actions. Unlike many firms that merely act as middlemen in litigation, Rosen Law Firm has direct experience and significant resources to fight for investor rights. The firm has successfully represented investors globally and has been involved in multiple high-profile cases, recovering hundreds of millions of dollars for clients. In 2019 alone, the firm secured over $438 million for investors. This history underscores the importance of selecting a firm with a proven success record in these types of legal battles.

Details of the Alleged Misconduct

The lawsuit claims that during the class period, the defendants presented misleading information regarding Altimmune’s IMPACT Phase 2b MASH trial, significantly inflating investor expectations. Reports suggest that the company manipulated trial results, creating a false impression about their effectiveness concerning fibrosis reduction. Investors learned that due to undisclosed information about the trial’s actual outcomes, they faced significant financial repercussions when the true results were made public.

What If You Decide Not to Participate?

If you choose not to join the class or to delay your decision, you remain an absent class member but cannot share in future recoveries unless you take action. You can also opt to represent yourself if you’re not comfortable being part of the class action. It’s crucial to consider your options carefully based on your investment circumstances.

Stay Informed

For ongoing updates regarding this case and others, follow Rosen Law Firm on LinkedIn, Twitter, and Facebook to remain informed about the latest developments.

This article serves as a vital reminder to all affected investors to act quickly and seek legal representation that prioritizes their rights and interests. Class action lawsuits provide a vital avenue for justice when corporate malfeasance affects a substantial number of stakeholders, and now is the moment to make your voice heard.

Disclaimer: This article is meant for informational purposes only and should not be construed as legal advice. Always consult a qualified attorney regarding legal matters.